Latigo Biotherapeutics

News

Quartet of biotechs join Nasdaq after stellar IPOs

Braveheart Bio, Latigo Biotherapeutics, Attovia Therapeutics, and BlossomHill Therapeutics have finalised their Nasdaq listings, raising over $1.2bn.

News

BlossomHill, Vogenx and Latigo reveal IPO plans

Three more biotechs have revealed their intentions to list on Nasdaq - BlossomHill, Vogenx, and Latigo - as 2026 heads for a record IPO haul.

News

Latigo raises $150m for non-opioid painkiller push

Latigo has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, raising $150 million in a Series B.

News

Freenome raises $254m for cancer tests, and other financings

Our round-up of recent biotech financings is headed by a $254 million private financing for cancer blood test specialist Freenome, with sizeable rounds for Cogent Bioscien

Quartet of biotechs join Nasdaq after stellar IPOs

BlossomHill, Vogenx and Latigo reveal IPO plans

Latigo raises $150m for non-opioid painkiller push

Freenome raises $254m for cancer tests, and other financings

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

Latigo Biotherapeutics

Editor's Picks